The human epidermal growth factor receptor (HER or ErbB) family of receptor tyrosine kinases plays a central role in different physiological functions mediating the transmission of extracellular signals to intracellular downstream pathways (1) .
The ErbB family includes four members, the epidermal growth factor receptor (EGFR; HER1 or ErbB1), HER2 (ErbB2), HER3 (ErbB3), and HER4 (ErbB4) (2) . The abnormal activation of these receptors has been linked with different pathological processes including malignant transformation (3) . For instance, overexpression of HER2 has been observed in breast, ovarian, and gastric cancer, and mutations of the EGFR have been described in non-small-cell lung cancer (3) . Strategies targeting these proteins, including the use of trastuzumab and lapatinib for the treatment of HER2 overexpressing breast cancer, trastuzumab for the treatment of HER2-amplified gastric cancer (3, 4) , and EGFR tyrosine kinase inhibitors in nonsmall-cell lung cancer (5) , have become routine clinical practice.
Activation of ErbB receptors causes stimulation of intracellular signaling cascades, which promote migration, invasion, proliferation, or survival, among others (1) . In pathological situations, such as in cancer, ErbB receptors can be activated by ligand binding, receptor overexpression, or structural alterations, including truncations and mutations (6) .
The HER3 receptor is a key member of the ErbB family and preferentially signals through the phosphatidylinositol 3-kinase pathway (7) . Formation of dimers between HER3 and HER2 seems to be crucial for the HER2-driven signals in those tumors with overexpression of HER2 (8) . Oligomerization of HER3 with other HER family receptors appears critical for its signaling function because HER3 lacks tyrosine kinase activity (3) . Given the fact that HER2-HER3 is considered the most active signaling dimer of the ErbB system, agents targeting this dimerization have been developed (9, 10) . This was the case for the antibody pertuzumab, which prevents the formation of HER2-HER3 dimers upon ligand binding (10, 11) .
Recent attention has focused on strategies to inhibit the activity of HER3 (12) . The rationale for targeting this receptor is based on the mentioned preclinical data and the increasing interest in the role of HER3-activating ligands such as neuregulin in cancer (11, 13) . Furthermore the positive results from clinical trials in HER2-positive breast cancer, in which pertuzumab was added to trastuzumab, have reinforced the interest in this receptor and led to the approval of pertuzumab for the first-line treatment of patients with HER2-positive, metastatic breast cancer (14) . In addition to pertuzumab, which binds the domain 2 of HER2, preventing its dimerization with HER3, other antibodies targeting HER3 are currently under development. These include those designed specifically against the ectodomain of HER3 and bivalent antibodies that target both HER2 and HER3 (15) .
Despite the clinical development of anti-HER3 therapies, the prognostic value of HER3 overexpression across different solid tumors remains unclear. It would be desirable to explore whether tumors in which HER3 is overexpressed are associated with worse outcome.
Here, we present a meta-analysis evaluating the prognostic impact of HER3 overexpression. The primary aim of this study was to evaluate the role of HER3 in relation to survival in solid tumors, thereby allowing more rational development of therapeutic strategies against this receptor.
Methods
This meta-analysis was carried out in accordance with preferred reporting items for systematic reviews and meta-analyses statement (16) .
Identification and Selection of Studies
Pubmed was searched for studies evaluating the expression of HER3 and survival in solid tumors from 1995 to 2012. We used the medical subject heading terms "HER3 and cancer" and "ErbB3 and cancer" and limited the results to human studies. We identified 289 and 448 entries, respectively. In addition we used the entry "HER3 or ErbB3" and the name of each specific solid tumor (for example HER3 or ErbB3 and breast cancer) to recognize additional studies. Eligibility criteria were the measurement of HER3 by immunohistochemistry (IHC), availability of survival data for at least 3 years, and publication in English. Studies evaluating gene expression of HER3 measured by polymerase chain reaction or fluorescence in situ hybridization were excluded from the analyses. Citation lists of retrieved articles were manually screened to ensure sensitivity of the search strategy. Study selection was based on the association of HER3 and survival.
Data Collection Process
Two authors (B. Seruga and F. Vera-Badillo) independently extracted information using predefined data abstraction forms. The following details were extracted: tumor type, number of patients, antibody used for the evaluation, method and score for its assessment, and cut-off for considering HER3 as overexpressed. Outcomes of interest were 3-and 5-year survival. In all cases, survival data were extracted from Kaplan-Meier curves. Specifically, the proportion of patients surviving to 3 and 5 years was extracted directly from the Kaplan-Meier curves for both HER3 normal (control group) and increased HER3 expression (experimental group).
Data Synthesis
The relative frequency of survival at 3 and 5 years between the control and experimental groups was expressed as an odds ratio (OR) and its 95% confidence interval (CI). A number of sensitivity analyses were prespecified. These included the evaluation of studies assessing the same disease site, studies including tumors with common HER2 overexpression, studies of tumors that frequently coexpress hormone receptors, and an analysis based on the IHC staining method.
Statistical Analysis
Data were combined into a meta-analysis using RevMan 5.1 analysis software (Cochrane Collaboration, Copenhagen, Denmark). Estimates of odds ratios were weighted and pooled using the Mantel-Haenszel random-effect model. Analyses were conducted for all studies, and differences between the subgroups were assessed using methods described by Deeks et al. (17) . All statistical tests were two-sided, and statistical significance was defined as P less than .05. No corrections were made for multiple comparisons.
Results

Description of Studies
We identified 12 studies that used IHC techniques for the assessment of HER3 expression. Characteristics of included studies are shown in Table 1 . Three studies evaluated colorectal cancer, two evaluated gastric cancer, two evaluated breast cancer, and one each evaluated melanoma, ovarian cancer, head and neck cancer, pancreatic cancer, and cervical cancer. A total of 1965 patients were included in those studies, and the median trial sample size was 128. The median followup of the six studies that reported follow-up times was 43.5 months (range = 24 to 65 months). All 12 studies reported data that allowed for the calculation of 3-year survival. Eleven studies presented data that allowed for assessment of 5-year survival.
Evaluation and Expression of HER3
A description of the antibodies used in the included studies is shown in Table 2 . Various antibodies were used for the evaluation of HER3 expression, although four studies used antibody C-17 (Santa Cruz Biotechnology, Santa Cruz, CA) and two studies used antibody MS-725-P (Neomarkers, Fremont, CA). The cutoff for overexpression depended on the staining score and the method used. Among the group determined as HER3 overexpressed, the median overexpression of HER3 staining was 42.2%. Melanoma, cervical, and ovarian tumors had the highest expression of HER3, with more than 50% of tumors considered overexpressed. Levels of overexpression in colorectal, gastric, and breast cancer ranged 20% to 60%. Most studies used a combined evaluation of cytoplasmic and membrane staining for determination of expression status (see Table 2 ). Takikita et al. (28) and Witton et al. (20) used only membranous staining, Spears et al. (19) used a kit evaluating HER2:HER3 dimers, and Begnani and Tanner (25, 27) used the Rajkumar score, a scoring system based on the fraction of positively stained tumor cells ( Table 2) .
Association of HER3 With Survival
The combined analysis of the 12 studies showed that HER3 overexpression was associated with worse 3-year survival (OR for death = 2.24, 95% CI = 1.77 to 2.83, P < .001) ( Figure 1 ). A similar result was observed for the 5-year survival (OR for death = 2.20, 95% CI = 1.75 to 2.76, P < .001) ( Figure 1 ). Sensitivity analysis by tumor type showed that for the three colorectal studies, no association of HER3 overexpression and survival was evident (OR for death = 0.82, 95% CI = 0.44 to 1.51, P = .52; OR = 1.07, 95% CI = 0.63 to 1.80, P = .80 for 3-year and 5-year OS, respectively) ( Table 3 ). This deviation from the pooled estimate was statistically significant (subgroup difference P < .001 and P = .002 for 3-year and 5-year survival, respectively).
Overexpression of HER3 was associated with worse outcome in gastric cancer (OR for death at 3 years = 3.71, 95% CI = 2.19 to 6.29; OR for death at 5 years = 2.99, 95% CI = 1.81 to 4.95) ( Table 3 ). This deviation from the pooled estimate was statistically significant for 3 years but not for 5 years (subgroup difference P = .03 and .21, respectively). Compared with normal HER3 expression, the pooled analyses of the two studies of breast cancer showed HER3 overexpression was associated with a greater magnitude of detrimental outcome (OR for death at 3 years = 2.48, 95% CI = 1.50 to 4.11, P < .001; OR for death at 5 years = 2.89, 95% CI = 1.84 to 4.53, P < .001). The magnitude of this effect was not statistically different from that of non-breast cancers (subgroup difference P = .66 and P = .17, respectively).
Among tumors in which HER2 overexpression is commonly observed (breast, gastric, and ovarian cancers), there was a stronger association between HER3 overexpression and unfavorable outcome compared with normal HER3 expression. At 3 years, the odds ratio for death among tumors in which HER2 overexpression is commonly observed was 3.12 (95% CI = 2.24 to 4.37) and was of statistically greater magnitude than that for tumors without common HER2 overexpression (OR = 1.57, 95% CI = 1.12 to 2.21; subgroup difference P = .004). Similar results were seen for death at 5 years among tumors in which HER2 overexpression is commonly observed (OR = 2.84, 95% CI = 2.09 to 3.88) versus among tumors without common HER2 overexpression (OR =1.64, 95% CI = 1.18 to 2.29; subgroup difference P = .02) ( Table 3 ). The magnitude of these results was heavily influenced by data from gastric cancer. However, for breast and ovarian cancers (tumors with frequent hormone receptor expression), compared with normal HER3 expression, overexpression was associated with higher odds of death at 3 years (OR = 2.77, 95% CI = 1.82 to 4.22; vs OR = 1.92, 95% CI = 1.40 to 2.63). This effect size was statistically greater than for tumors in which hormone receptors are not commonly expressed (subgroup difference P = .02). Similar results were seen for death at 5 years (OR = 2.75, 95% CI = 1.86 to 4.08; vs OR = 1.97, 95% CI = 1.50 to 2.60; subgroup difference P = .30) ( Table 3) .
Influence of HER3 Staining and Outcome
There was no difference in the odds of death at 3 years or at 5 years between studies utilizing cytoplasmic HER3 staining and those using membranous staining (P for subgroup differences = 0.61 and 0.95, respectively) ( Table 3) .
Discussion
ErbB receptors have been implicated in the etiology of a substantial number of solid tumors. Because HER3 is thought to play a key role in signaling, proliferation agents against this receptor are currently under development (12) . In this study, we metaanalyzed the published data about the expression of HER3 in solid tumors and their association with survival for studies that evaluated HER3 by IHC. We selected only studies that evaluated HER3 by IHC because this is the standard method for the evaluation of other ErbB-family proteins (eg, HER2 and EGFR) and there was consistency in the evaluation process among studies.
Results show that overexpression of HER3 was associated with worse survival for all studies analyzed except for two studies of colorectal cancer (21, 22) . These results can be observed at both 3 and 5 years. Among the tumor types evaluated, gastric cancer was the tumor type most linked with a worse outcome for patients who expressed high levels of HER3 (23, 25) . That this tumor commonly overexpresses HER2 suggests that the family of ErbB receptors and ligands may have an important role in this tumor type. In this disease site, the cutoff for overexpression of HER3 varied from 35% to 60% of cells (23, 25) .
This effect was maintained when other disease sites frequently associated with HER2 expression (breast and ovarian cancers) were added (19,23, 25,27 ). This suggests that interaction between HER2 and HER3 may be important in these tumors. Unfortunately, differential survival rates by individual HER2 and HER3 overexpression were not reported; therefore, this hypothesis cannot be tested using available data. The impact of HER3 overexpression in both HER2-normal and HER2-overexpressing tumors, therefore, requires further assessment. Nuclear and cytoplasmic staining † Rajkumar score,resulting from the product of the score for the fraction of positive cells (range = 0 to 4 [0 = <10% of positively stained cells; 1 = 10%-25%; 2 =26%-50%; 3 = 51%-75%; and 4 = >75%]) and the score for staining intensity (range = 0 to 3). Positive: Slices with scores >8 were classified Melanoma (26) approximately 65.0%
Clone C-17, 1:50 dilution; Santa Cruz, CA Cytoplasmic and membrane Semiquantitative scoring system following the German immunohistochemical scoring (GIS) system The final immunoreactive score equaled the product of the percentage of positive cells times the average staining intensity. Positive: high GIS > 6 Ovary (27) 53.4% C-17, rabbit polyclonal antibody; dilution: 1:25; Santa Cruz, CA Cytoplasmic and membrane Rajkumar score Positive: Slices with scores >8 were classified Head and Neck (28) 8.8% RTJ.2, mouse monoclonal antibody; Santa Cruz, CA Cytoplasmic: scores of 0,+1, +2, +3 for increasing intensity and "continuity" of staining of the cell membrane Positive: >3 Cervix (29) 55.5% MS-725-P, mouse antibody; Neomarkers
No mentioned cytoplasmic and membrane Quantitatively scored by ChromaVision cellular imaging technology for each patient (intensity scale based on pixel density, 0-4) Positive: ≥0.8 * Membrane staining: proximity ligation assay. It is a method that allows detection of the cellular distribution of endogenousproteins at a single-molecule level and can be used to detect interaction between proteins such as protein-protein dimers. † The predominant pattern of HER3 staining was in the cytoplasm; only two tumors showed membrane staining (scores 1+ and 2+). Odds ratios for each trial are represented by the squares, the size of the square represents the weight of the trial in the meta-analysis, and the horizontal line crossing the square represents the 95% confidence interval. The diamonds represent the estimated pooled effect (labeled total) using the Mantel-Haenszel random-effect model. All P values are two-sided. Interestingly, overexpression of HER3 in colorectal studies was not associated with a worse outcome. HER2 has not been identified as a key element in the oncogenesis of colon cancer, and data about the role of HER3-activating ligands in this tumor type is also weak (11, 30) .
We observed that overexpression of HER3, ranging from 20% to 60% depending on the tumor type, is present in a substantial number of tumors; most studies used a combined evaluation of HER3 staining in the cytoplasm and membrane. However, the pooled analyses of studies that evaluated HER3 in the cytoplasm or in the membrane did not showed statistically significant differences.
A consistent and reproducible method to evaluate HER3 should be developed to better identify patients who may be more responsive to anti-HER3 therapies currently under clinical evaluation. Furthermore, evaluation of ligands that activate this receptor should help in the identification of those tumors that have activated HER3 and that would be sensitive to these therapies. This process should mirror that for HER2, for which the development of trastuzumab occurred synchronously with an accurate technique to evaluate the biomarker (31, 32) .
These analyses have several important implications. First, they show that overexpression of HER3 is associated with worse outcome, which suggests that this protein may be a useful druggable therapeutic target. This is important because the lack of kinase activity of HER3 raised doubts about the clinical relevance of targeting HER3 (33) . However, several recent findings support the targeting of HER3 in cancer (12) . Thus, expression and signaling by HER3 has been described in tumors from patients resistant to anti-HER therapies (34) . Moreover, expression of HER3 ligands, with establishment of autocrine loops that favor tumor growth, have been reported in certain tumors (35, 36) Second, it identifies a subtype of tumors with worse outcome potentially those in which other ErbB receptors are also overexpressed. Third, it identifies a subgroup of tumors. Fourth, it highlights the importance of the development of an accurate biomarker for its assessment. Finally, the analyses emphasize the value of identifying surrogate markers of HER3 activation. We and others have suggested the HER3 ligand neuregulin as a potential key marker (11, 15, 35, 36) . Following this approach, some phase I trials of HER3-targeting antibodies are selecting patients based on heregulin expression (a type of the HER3-ligands termed neuregulins) (Clinical Trial: NCT00911898, NCT0109746033; http://www. clinicaltrials.gov) (37), or enriching populations with patients with certain disease sites (eg, breast and ovarian cancers; see Table 4 ). These analyses have limitations. First because this is a literature-based analysis, it is compromised by the potential for publication bias, whereby predominantly positive results were published, thus inflating our estimate for the association between HER3 and poor outcome. Second, there is no accepted and validated method for assessment of HER3 expression. Therefore, there may be substantial heterogeneity, which may not be fully accounted for by our use of random-effects modeling. An internationally accepted and validated method for HER3 testing is warranted. Finally, we were unable to pool hazards of death because time-to-death data were not reported. Instead, we reported the odds of death at two fixed time points. This measure is less robust because it does not take into account the duration of survival until death. However, this was the only feasible method with the data available.
In conclusion, our analyses show that overexpression of HER3, as measured by IHC, is associated with a worse prognosis in different tumor types, which suggests that the development of strategies against this receptor could be a reasonable therapeutic approach. Further data are required about the potential for greater impact in tumors with overexpression of both HER2 and HER3.
